PET for Drug Development and Evaluation

  • D. Comar

Part of the Developments in Nuclear Medicine book series (DNUM, volume 26)

Table of contents

  1. Front Matter
    Pages i-viii
  2. Introduction

    1. Bengt Långström, Mats Bergström, Per Hartvig, Sven Valind, Yasuyoshi Watanabe
      Pages 37-50
  3. Psychiatry

    1. Christer Halldin, Carl-Gunnar Swahn, Lars Farde, Göran Sedvall
      Pages 55-65
    2. Christian Foged, Per Karlsson, Birte K. Skrumsager, Lars Ynddal, Erik B. Nielsen, Christer Halldin et al.
      Pages 73-81
    3. Victor W. Pike, Ian A. Cliffe, Allan Fletcher, Susan P. Hume, Julie A. McCarron, Sharon Ashworth et al.
      Pages 93-108
    4. Jesús Benavides, Pascale Abadie, Jean Claude Baron, Bernard Scatton
      Pages 109-122
  4. Neurology

    1. Adriaan A. Lammertsma, Christopher J. Bench
      Pages 155-165
    2. Paul M. Grasby, Karl J. Friston
      Pages 167-177
    3. Paul Morrish, James Rakshi, David J. Brooks
      Pages 179-188
    4. Jorga Karin, Leenders Klaus Leonhard, Günther Ilonka, Psylla Maria
      Pages 189-195
    5. B. Mazière, R. Horowski
      Pages 197-203
    6. Klaus Leonhard Leenders, Angelo Antonini
      Pages 205-214

About this book

Introduction

Can drug development and evaluation be improved by the use of positron emission tomography (PET)? PET is now well established and many PET centres participate in networks that warrant the quality of their research. PET allows one to follow the effect of a drug on a variety of patients' metabolic parameters. In addition, PET may be used to follow the fate in vivo of a compound, allowing visualisation of its binding to specific receptors and a direct study of the mechanism of drug action in normal and pathological situations.
The book shows the fields in which PET offers new and unique information for the development of drugs (conception, toxicity, pharmacokinetics and metabolism, clinical research, and relations between clinical and biological effects) and evaluates fields in which PET may shorten the development time of drugs.
Audience: Professionals in the pharmaceutical industry in all areas of drug discovery and pharmacology, pre-clinical testing, pharmacokinetics and metabolism, clinical evaluation, registration and regulatory affairs. Government health authority representatives who assess data and documentation on new drug development and radiopharmaceuticals. Academic experts concerned with any of these areas.

Keywords

brain clinical research diagnosis dopamine drug drug development drug discovery kinetics metabolism pharmacokinetics pharmacology positron emission tomography (PET) research tomography toxicity

Editors and affiliations

  • D. Comar
    • 1
  1. 1.Hôpital Neuro-cardiologiqueLyonFrance

Bibliographic information

  • DOI https://doi.org/10.1007/978-94-011-0429-6
  • Copyright Information Kluwer Academic Publishers 1995
  • Publisher Name Springer, Dordrecht
  • eBook Packages Springer Book Archive
  • Print ISBN 978-94-010-4191-1
  • Online ISBN 978-94-011-0429-6
  • About this book
Industry Sectors
Pharma